Fuji Pharma
Biosimilar developer, Japan. 5 development products across 5 molecules: aflibercept, denosumab, filgrastim, golimumab, ustekinumab.
About Fuji Pharma
Fuji Pharma is among the most active Japanese biosimilar developers, with five approvals: filgrastim in 2012, Japan's first, then ustekinumab, denosumab, aflibercept and golimumab between 2023 and 2025, each the first or among the first of its kind in Japan. Fuji Pharma does not name the developers of its products, and none has been filed outside Japan.
Portfolio by market
| Molecule | Product | FDA | EMA | MHRA | PMDA | HC | CDSCO | EDE | Markets |
|---|---|---|---|---|---|---|---|---|---|
| Aflibercept | Aflibercept BS NIT | · | · | · | Sep 2025 | · | · | · | 1/7 |
| Denosumab | Denosumab BS F | · | · | · | Sep 2025 | · | · | · | 1/7 |
| Filgrastim | Filgrastim BS F / Mochida | · | · | · | Nov 2012 | · | · | · | 1/7 |
| Golimumab | Golimumab BS F | · | · | · | Sep 2025 | · | · | · | 1/7 |
| Ustekinumab | Ustekinumab BS F | · | · | · | Sep 2023 | · | · | · | 1/7 |
Month shown is the first approval or registration of that product in that market.
Companies on the same molecules
Developers whose portfolios overlap most with Fuji Pharma, by number of shared molecules. Overlap is the clearest sign of who competes with whom for the same tenders and licensing partners.
Chronology
- PMDANov 2012Filgrastim BS F / Mochida, filgrastim
- PMDASep 2023Ustekinumab BS F, ustekinumab
- PMDASep 2025Aflibercept BS NIT, aflibercept
- PMDASep 2025Denosumab BS 120 mg RM F, denosumab
- PMDASep 2025Golimumab BS F, golimumab
Compare Fuji Pharma with other developers on the comparison page.
Considering a partner, a licence or a new market for a biosimilar portfolio? EvySaif's regulatory strategy and value dossier work covers the regulatory and market-access side of that decision.
Planning your biosimilar strategy?
EvySaif can help assess your regulatory pathway, clinical evidence requirements and market-entry strategy across India, UAE and other target markets.
Talk to a biosimilar regulatory consultant